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Dissecting the genetics of cardiomyopathy in India: A tale of ten steps
Reliable data on the prevalence of cardiovascular disease (CVD) from the Indian sub-continent do not 
exist. However, compared to the global average, the public-health burden attributable to CVD is very 
high in India (Goyal and Yusuf 2006). Based on cross-sectional surveys conducted in Indian populations 
(Gupta 2004, 2005), the prevalence of coronary heart disease (CHD) was estimated to be 3–4% in rural 
areas and 8–10% in urban areas in 2003. These prevalence estimates were two- to six-fold higher than 
those estimated 40 years ago, and may be underestimates because of incompleteness of our cause-of-death 
statistics. CVD, as is well known, is caused by an interaction between genetic and environmental factors. 
Variants in many genes have been found to be associated with CVD in populations, some of which also co-
segregate with CVD in families. However, replication of association or linkage fi ndings has been diffi cult. 
The diffi culties stem from various complexities: heterogeneous nature of the CVD phenotype, possible 
involvement of multiple genes with variable effects from one family/population to another, limited 
sample sizes and population stratifi cation. In the dissection of a common disease such as CVD, one way 
to reduce the complexity arising from heterogeneity of phenotype is to recognize, defi ne and study a sub-
phenotype that is clinically more homogeneous. CHD is the most signifi cant component of CVD. Even 
CHD is clinically heterogeneous. A common cause of heart failure is impaired contraction of one or both 
ventricles of the heart in the absence of signifi cant coronary artery disease. Impairment of contraction of 
ventricles may be due to enlargement (dilated cardiomyopathy), thickening (hypertrophic cardiomyopathy)
or rigidity (restrictive cardiomyopathy) of the heart muscle. Cardiomyopathy is a leading cause of
cardiac transplantation. The high morbidity and mortality associated with cardiomyopathy underscores 
the need for a better understanding of the underlying molecular events leading to heart failure in 
cardiomyopathy. 
Defective cardiac-myosin binding protein C, a component of fi laments in cardiac muscle cells, results 
in distorted sarcomeres – the smallest functional units of muscle. The gene that produces this protein 
is called MYBPC3. Variants in this gene have been associated with cardiac disease in various world 
populations. Dhandapany et al (2009) has recently identifi ed a 25-bp deletion in an intron of MYBPC3 
that is associated with cardiomyopathy in south Asia. This is an important fi nding from a clinical and 
molecular genetic standpoint. A DNA diagnostic test to assess whether an individual has inherited this 
deletion will have a signifi cant predictive value.
Aside from signifi cance, the study serves as a model for dissection of a complex disease such as 
CHD. This is to be emphasised. First, the authors reduced the clinical heterogeneity of CHD by focussing 
on a subphenotype – heart failure due to cardiomyopathy. This strategy enhances the chance of gene 
identifi cation. True, the identifi ed variant/mutation in MYBPC3 cannot explain the garden-variety CHD 
phenotype, but in any case one does not expect a single variant/mutation in a single gene to explain any 
complex phenotype. At least this strategy serves to identify and helps to predict – and thus possibly 
prevent – heart failure in a large number of individuals. Second, the authors built their hypothesis of 
the association of the 25-bp deletion with cardiomyopathy when they observed (possibly a chance 
observation) an enhancement of the frequency of this deletion in a small number of individuals with 
cardiomyopathy. Third, the authors then went on to test their hypothesis with much larger sample sizes 
(354 affected individuals and 238 healthy controls, matched for appropriate covariates). The hypothesis 
was accepted. The odds-ratio of having cardiomyopathy was 5.3-fold higher if one carried the 25-bp 
deletion than if one did not. Fourth, the authors went on to cross-validate this inference in an independent 
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sample of 446 affecteds and 466 healthy controls. The odds-ratio (6.99) was again statistically highly 
signifi cant (cross-validation is crucial to guard against false positive inferences). In genetic association 
studies false positive results can also arise due to heterogeneity of ancestries of selected affecteds and 
controls (a phenomenon called “population stratifi cation”). The fi fth highlight of this study is that the 
authors generated extensive and relevant genetic data from judiciously selected population groups and 
carried out appropriate statistical tests to rule out the possibility of having drawn a false positive inference 
arising from population stratifi cation.
An individual can be either homozygous or heterozygous for the 25-bp deletion. Are the clinical 
manifestations of possessing two copies of the deletion allele the same as that of possessing one copy of 
the allele? This was the sixth issue considered in this study. The authors gathered data from 28 unrelated 
families comprising 120 individuals. Unfortunately, the number of homozygotes was too few to draw 
any strong conclusions, although the homozygotes seemed to be vulnerable to sudden cardiac death. The 
heterozygote carriers of the deletion showed an age-dependent phenotype. Young heterozygote carriers 
were mostly asymptomatic or mildly symptomatic, but ~90% of the older heterozygote carriers in these 
families were symptomatic. Symptoms in carriers started to develop by about the third decade of life. 
Some exceptions were noted, indicating phenotypic heterogeneity within the heterozygous genotype.
The seventh highlight of the study was that the authors investigated the risk induced by the deletion. 
They analysed RNA and protein from the endomyocardial biopsy specimens of two young heterozygous 
individuals, who were 25 and 32 years old. Their cardiac MyBP-C cDNA revealed two transcript structures: 
a normal transcript and a mutated allele with exon-skipping. However, the altered protein could not be 
detected in the biopsied tissue samples. Could the altered protein distort the normal structure of the 
sarcomere? To investigate this, the authors expressed the myc-tagged altered protein along with wild type 
(WT) protein in neonatal rat cardiomyocytes, and stained these with antibodies to the myc. The results 
of this experiment showed that the normal sarcomeric architecture was distorted as a result of aberrant 
incorporation of the altered protein. This disorganization perhaps leads to pathogenesis. It has been 
hypothesized that the accumulation of the altered protein might disrupt the cellular homeostasis and initiate 
late-onset cardiomyopathy; a possible explanation for the vast majority of individuals with the 25-bp 
deletion remaining healthy until the third decade of their life. Since the altered protein could not be detected 
in the tissue, this causal explanation could not be confi rmed. More evidence is required to prove casuality. 
Since carriers of the 25-bp deletion remain asymptomatic for the fi rst three decades of their life, a large 
number of individuals in a population would not even know that they are carriers. In other words, they 
may be unknowingly sitting on a volcano, waiting to erupt. What is the frequency of the 25-bp deletion 
allele in the general Indian population? The authors screened 6,273 individuals belonging to 107 ethnic 
populations across 35 States of India. They found that the allele frequency across populations ranged 
from 2% to 8%; southern and western States showed signifi cantly higher frequencies of the deletion allele 
compared with the north and northeastern States. If indeed possessing even one copy of the deletion allele 
had deleterious consequences, why was the deletion allele not eliminated? Based on inferred haplotype 
backgrounds of chromosomes carrying the deletion and the normal alleles, they authors did not fi nd major 
selective effects. They have argued that since a carrier of the deletion allele remains asymptomatic till 
about 30–40 years of age, possessing this allele did not impact on family size. Further evidence may be 
sought from families of carriers who do not adopt family-planning practices: hard to fi nd, but possibly 
obtainable from rural India.
The deletion allele is common throughout India. Is it also common in other regions of the world? Sampling 
of populations from 5 continents showed that except for Pakistan, Sri Lanka, Indonesia and Malaysia, the 
deletion allele is absent from other regions of the world. Did the allele arise in India? Perhaps, yes … about 
33,000 years ago, after the initial settlers arrived in India.
The work embodied in this paper represents a model study on dissecting the genetics of a complex 
disorder, characterized by judicious choice of a nearly-homogeneous sub-phenotype, building on cues 
obtained from earlier studies, conduct of population and family based studies with large sample sizes 
to identify an associated genetic variation, cross-validation, excluding a known factor (“population 
stratifi cation”) that leads to false positive inferences, genotype-phenotype correlation, functional 
validation (which remains somewhat weak in this work), and drawing relevant population-genetic and 
evolutionary inferences.
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